Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Aldesleukin 22000000 UNT Injection [Proleukin]

Known as: ALDESLEUKIN 1.1 mg in 1 mL INTRAVENOUS INJECTION [PROLEUKIN], Proleukin 22,000,000 UNT Injection, aldesleukin 1.1 mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [Proleukin] 
 
National Institutes of Health

Related topics

Related topics

8 relations
AldesleukinInjectionMannitolProleukin
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Antigen-Specific Regulatory T Cells and Low Dose of IL-2 in Treatment of Type 1 Diabetes
Regulatory T cells (Tregs) play an important role in preventing effector T-cell (Teff) targeting of self-antigens that can lead… Expand
Is this relevant?
2016
2016
Abstract 558: Durable antitumor activity of the CD122-biased immunostimulatory cytokine NKTR-214 combined with immune checkpoint blockade
Background: While immune checkpoint blockade is a promising therapeutic approach, combination with agents that modulate… Expand
Is this relevant?
2014
2014
OP0104 Low-Dose Interleukin-2 Therapy Caused Selective Expansion of Regulatory T Cells Together with RAPID Reduction of Disease Activity in A Patient with Severe Refractory Sle
Background SLE is characterized by the breakdown of immune tolerance towards nuclear autoantigens. Aberrant activation of… Expand
Is this relevant?
2014
2014
Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin® (HD IL-2) and Ipilimumab Yervoy® ) in patients with metastatic melanoma (proclivity 02)
Prometheus Laboratories, San Deigo, CA, USA Full list of author information is available at the end of the article Figure 1 Open… Expand
Is this relevant?
2014
2014
A multi-center study of high dose Aldesleukin (Proleukin® (HD IL-2) + Vemurafenib Zelboraf® ) therapy in patients with BRAFV600 mutation positive metastatic melanoma (proclivity 01)
A multi-center study of high dose Aldesleukin (Proleukin®(HD IL-2) + Vemurafenib Zelboraf®) therapy in patients with BRAF… Expand
Is this relevant?
2011
2011
Prognostic significance of peripheral blood CD8highCD57+ lymphocytes in bladder carcinoma patients after intravesical IL-2.
BACKGROUND The objective of this study was to evaluate the recurrence-preventing effect of intravesical instillations of… Expand
Is this relevant?
2004
2004
Comparison of Pharmacokinetics and Pharmacodynamics of two different dosing regimens of Proleukin® (IL-2) in Combination with rituximab: The effect of NK cell expansion.
Background: Published results from studies testing two different dosing regimens of IL-2 in combination with rituximab have shown… Expand
Is this relevant?
2004
2004
Investigation of FcγR Polymorphisms and Response to IL-2 (Proleukin®) and Rituximab Treatment in Rituximab-Resistant NHL Patients: Importance of the F/F Polymorphism at Position 158 of the Fcγ.
Background: Antibody-dependent cellular cytotoxicty (ADCC) is an important mechanism of rituximab activity. Genetic polymorphisms… Expand
Is this relevant?
2001
2001
Persistierende knotige Lokalreaktion mit Lymphom-ähnlichen Infiltraten nach s.c-Injektion von Interleukin-2
ZusammenfassungInterleukin-2 (IL-2) kommt aufgrund seiner immunstimulatorischen Wirkung auf T-Zellen in der Tumortherapie von… Expand
Is this relevant?
1994
1994
Treatment of Patients with Metastatic Renal Cell Carcinoma with Subcutaneous Recombinant Interferon-Alpha 2b and Continuous Infusion of Recombinant lnterleukin-2: A Phase II Study
Background: On the basis of encouraging preclinical data, we investigated the combination of the 2 agents recombinant interferon… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE